Skip to content
Medical Health Aged Care

Dementia Australia supports Biloela and Theodore

Dementia Australia 3 mins read

Are you concerned about your memory or worried that someone you know may have dementia? Dementia Australia is offering support in Biloela and Theodore between 25 September and 6 October 2023.

It is estimated there are almost 80,000 people living with dementia in Queensland. Without a medical breakthrough this number is expected to increase to more than 174,000 people living with dementia by 2058.

The Dementia Australia sessions are an opportunity for people living with dementia, their carers, family, and friends to attend free education to better understand dementia and to discuss the support and services Dementia Australia can provide. Please note, bookings are essential.


Understanding Dementia

This session provides an introduction to dementia including an overview of the different types of dementia, diagnosis, planning ahead and how to support someone living with dementia.

  • Monday 25 September 1pm-2:30pm in Biloela
  • Tuesday 26 September 10am-11:30am in Theodore


Carer Gateway – Information Session

This session provides information for families and carers on how to access free dementia specific services including counselling, coaching, connecting with other carers and respite.

  • Monday 25 September 3pm-4pm in Biloela


Communication and Dementia

This session provides information on dementia, the way we communicate and how changes in communication can occur as a result of dementia.

  • Tuesday 26 September 12:30pm-3pm in Theodore
  • Thursday 28 September 9:30am-12pm in Biloela


Worried About Your Memory?

This session provides information on memory and common changes that may occur with ageing.

  • Tuesday 26 September 12:30pm-3pm in Theodore
  • Wednesday 27 September 1pm-3:30pm in Biloela


Understanding Changes in Behaviours

This session provides an introduction to dementia and changes to the brain, effects on behaviour and the impacts of changed behaviour.

  • Wednesday 27 September 1pm-4pm in Biloela


Grief, Loss and Dementia

This session provides an overview of the grief, loss and emotional impact of the changes caused by dementia.

  • Thursday 28 September 9am-12pm in Biloela


EDIE for Family Carers

This session enhances knowledge of dementia through virtual reality technology that allows participants to see the world through the eyes of a person living with dementia.

  • Tuesday 3 October 1pm-4:30pm in Biloela
  • Friday 6 October 8:30am-12pm in Theodore


Carer Wellness Program

This group session is designed to support positive health and wellbeing outcomes for a carer, family or friend of a person living with dementia.

  • Wednesday 4 October 9:30am-3pm in Biloela
  • Thursday 5 October 9:30am-3pm on Theodore

 

Bookings are essential. Visit www.dementia.org.au/brainhub/biloela-theodore for details and to register. You can also call the National Dementia Helpline to register for this course on 1800 100 500. The National Dementia Helpline is available 24 hours a day, seven days a week.

 

Dementia Australia is the source of trusted information, education and services for the estimated more than 400,000 Australians living with dementia, and the more than 1.5 million people involved in their care. We advocate for positive change and support vital research. We are here to support people impacted by dementia, and to enable them to live as well as possible. No matter how you are impacted by dementia or who you are, we are here for you.

For support, please contact the National Dementia Helpline on 1800 100 500. An interpreter service is available. The National Dementia Helpline is funded by the Australian Government. People looking for information can also visit dementia.org.au

-Ends-

Media contacts: Megan Jones, Media & Communications Advisor, megan.jones@dementia.org.au, 0411 461 678

When talking or writing about dementia please refer to Dementia-Friendly Language Guidelines.

Note to Editors:

We request, where possible, details for the National Dementia Helpline 1800 100 500 appear alongside news stories about dementia, as these stories often prompt questions or concerns:

If this story has prompted any questions or concerns, please call the National Dementia Helpline 1800 100 500 (24 hours, 7 days a week) or visit dementia.org.au.

 

Media

More from this category

  • Medical Health Aged Care
  • 30/11/2023
  • 06:05
Royal Australian College of GPs

RACGP calls on Queensland to reduce pressure on hospitals and improve the health of Queenslanders

As Queensland hospitals grapple with devastating ramping, bed shortages, and delays, there has never been a more crucial time for the state to invest in general practice to keep people healthy in the community, says the Royal Australian College of GPs (RACGP). A perfect storm of factors, including an aging population, epidemic of chronic disease, and acute workforce shortages, is putting increasing pressure on Queensland’s hospitals, prompting the RACGP to make its first Budget submission to the state government. RACGP Queensland Chair Dr Cathryn Hester said investment in general practice is key to reducing pressure on Queensland's hospital system. “Queensland’s…

  • General News, Medical Health Aged Care
  • 30/11/2023
  • 06:00
UNSW Sydney

Meet Viv: an AI character fostering companionship for people with dementia

With a view to improving the lives of people living with dementia, UNSW researchers have come up with a world-first: an AI driven companion.…

  • Contains:
  • Medical Health Aged Care
  • 29/11/2023
  • 23:22
Clairvoyant Therapeutics

Clairvoyant Surpasses 50 Per Cent Randomization in its Phase 2b Psilocybin Therapy Trial for Alcohol Use Disorder

VANCOUVER, BC / ACCESSWIRE / November 29, 2023 / Clairvoyant Therapeutics Inc. (www.clairvoyantrx.com), the clinical-stage pharmaceutical company developing psilocybin therapy for alcohol use disorder (AUD), today announced that it has randomized more than 50 per cent of the expected 128 subjects for its 24-week Phase 2b clinical trial of synthetic psilocybin (25mg oral capsule). The double-blind, randomized controlled trial was initiated in October 2022 and is designed to assess multiple efficacy and safety endpoints."We are pleased that the pace of subject enrollment is at the upper end of our expectations. We are on track for an interim data read out…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time your distribute with Medianet. Pay per release or save with a subscription.